HELP   |   REGISTER   |   LOGIN
RSS
The Individual Investor Intelligence Network
HOME  |  GLOBAL MACRO  |  MEDIA  |  TECHNOLOGY  |  BIOTECH  |  COMMODITIES  |  EDUCATION  |  IU25 INDEX  |  ABOUT US
Comments
View Comments: Oldest First | Newest First | Threaded View
Page 1 / 3   >   >>
Drivewaygirl
User Rank
Platinum
Nice!
Drivewaygirl   4/19/2012 12:21:22 PM
NO RATINGS
Nice to see the best-performing stock in the S&P 500 this morning was an IU25 company. Good selection, Scott.

Tenacious
User Rank
Platinum
Re: Nice!
Tenacious   4/19/2012 12:25:22 PM
NO RATINGS
Ditto. What's Gilead up--like 30% this year?

Scott Raynovich
User Rank
Blogger
Re: Nice!
Scott Raynovich   4/19/2012 12:47:59 PM
NO RATINGS
Not quite that good! GILD is up 12% in the last three months and 30% in the last year. If you were really good, though, you could have gotten some on the dip down to $35 and you'd be up more than 50%.

Noreen Seebacher
User Rank
Blogger
Re: Nice!
Noreen Seebacher   4/19/2012 12:49:22 PM
NO RATINGS
I wouldn't complain about 30% in a year.

driven
User Rank
Iron
Re: Nice!
driven   4/19/2012 1:19:51 PM
NO RATINGS
Good news for investors, even better news for people with hep C.

ProfR
User Rank
Platinum
Take over candidate?
ProfR   4/19/2012 3:22:24 PM
NO RATINGS
So do you think they are an acquisition candidate?

Scott Raynovich
User Rank
Blogger
Re: Take over candidate?
Scott Raynovich   4/19/2012 5:24:36 PM
NO RATINGS
Yes I do though it's a big company would have to be a Big Pharma buy. But I don't think they will sell.

Value Hiker
User Rank
Platinum
Re: Take over candidate?
Value Hiker   4/19/2012 8:48:17 PM
NO RATINGS
@Scott, who can be the potential buyer of Gilead: pfizer, merck, or BMY? But BMY seems won't buy Gilead due to its competitive acquisition of Inhibitex.

Noreen Seebacher
User Rank
Blogger
Hep C market
Noreen Seebacher   4/19/2012 9:27:10 PM
NO RATINGS
Market-research firm Decision Resources estimates the overall hepatitis C virus drug market will experience significant growth, expanding from almost $1.7 billion in 2010 to $14.4 billion in 2015 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Thereafter, the market will decrease to $11.2 billion in 2020, owing to a decline in the size of the treatment-eligible population due to declining prevalence and effective new regimens.

Decision Resources also estimates that by 2015, Gilead's GS-7977 Plus Ribavirin Will Displace the Current Proprietary Clinical Gold Standard, Telaprevir in Combination with Peg-IFNα/Ribavirin.

Noreen Seebacher
User Rank
Blogger
Re: Hep C market
Noreen Seebacher   4/19/2012 9:37:11 PM
NO RATINGS
This puts Hep C in perspective: Scott D. Holmberg, chief of the epidemiology and surveillance branch for viral hepatitis at the U.S. Centers for Disease Control and Prevention, reported at a major liver conference in November that the number of people who die with hepatitis C in the U.S. now exceeds the number of those who die of HIV/AIDS.

Page 1 / 3   >   >>




The blogs and comments posted on Investor Uprising do not reflect the views of Investor Uprising, PRNewswire, or its sponsors. Investor Uprising, PRNewswire, and its sponsors do not assume responsibility for any comments, claims, or opinions made by authors and bloggers. They are no substitute for your own research and should not be relied upon for trading or any other purpose.
Latest Blogs
Telecom-equipment maker Ciena is a stock trader’s dream, as long as the timing is correct.
The FTC is offering a $50,000 cash prize to the person or group that can come up with a solution to those annoying robocalls.
Akamai is in the middle of four significant tech trends.
John Malone of Liberty Media will be taking over Sirius XM satellite radio when the existing CEO Mel Karmazin steps down. What's it mean?
Demand for students of the humanities exists, despite widespread aspersions on the discipline.
IU Education
Resources to help you become a better investor
IU Education
Quick Poll
Investor Uprising on Twitter
Investor Uprising on Twiter
Market Chatter
Like Us on Facebook
Top 10 IU Hot Topics
25 market-moving companies we're tracking
PR Newswire's Terms of Use Apply | Privacy | Contact Us
Copyright © 1996-2013 PR Newswire Association LLC. All Rights Reserved.
A UBM plc company.
PR Newswire